Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with Rosiglitazone

Table 3

Changes of serum ALS levels by treatment in subjects categorized as nonobese (BMI < 24 kg/m²) or obese (BMI ≥ 24 kg/m²).

	Nonobese subjects (BMI < 24 kg/m^2)		Obese subjects (BMI ≥ 24 kg/m^2)
	Placebo	RSG	Placebo	RSG
𝑁	10	9	21	21
Baseline ALS levels, mU/mL	1350.0±574.2	1675.8±1030.1	1253.9±406.3	1388.8±761.3
24-week ALS levels, mU/mL	1633.5±582.6	1386.5±627.3	1148.2±439.8	1345.4±593.6
Difference	283.5±517.4	−289.2±634.0^∗	−105.7±251.1	−43.4±572.9

^∗𝑃=0.0275 compared to the subjects in the placebo group. The 𝑃 value is from the Wilcoxon rank-sum test. ALS: acid-labile subunit; BMI: body mass index; RSG: rosiglitazone.